CS
ACOR

Credit Suisse’s Acorda Therapeutics ACOR Stock Holding History

Credit Suisse’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-501
Closed -$172K – 4384
2019
Q3 		$172K Sell
501
-7
-1% -$3.81K ﹤0.01% 3896
2019
Q2 		$467K Buy
508
+23
+5% +$28.3K ﹤0.01% 3449
2019
Q1 		$774K Sell
485
-174
-26% -$313K ﹤0.01% 3083
2018
Q4 		$1.23M Buy
659
+12
+2% +$26.1K ﹤0.01% 2620
2018
Q3 		$1.52M Buy
647
+32
+5% +$99.1K ﹤0.01% 2557
2018
Q2 		$2.12M Sell
615
-72
-10% -$220K ﹤0.01% 2404
2018
Q1 		$1.95M Sell
687
-60
-8% -$180K ﹤0.01% 2445
2017
Q4 		$1.92M Sell
747
-108
-13% -$307K ﹤0.01% 2464
2017
Q3 		$2.43M Sell
855
-121
-12% -$319K ﹤0.01% 2379
2017
Q2 		$2.31M Sell
976
-343
-26% -$680K ﹤0.01% 2141
2017
Q1 		$3.32M Buy
1,319
+154
+13% +$443K ﹤0.01% 1953
2016
Q4 		$2.63M Buy
1,165
+346
+42% +$823K ﹤0.01% 2204
2016
Q3 		$2.05M Sell
819
-280
-25% -$835K ﹤0.01% 2364
2016
Q2 		$3.36M Buy
1,099
+363
+49% +$1.18M ﹤0.01% 1934
2016
Q1 		$2.34M Buy
736
+231
+46% +$959K ﹤0.01% 2082
2015
Q4 		$2.59M Sell
505
-187
-27% -$817K ﹤0.01% 2096
2015
Q3 		$2.2M Sell
692
-231
-25% -$896K ﹤0.01% 2189
2015
Q2 		$3.69M Buy
923
+375
+68% +$1.45M ﹤0.01% 2007
2015
Q1 		$2.19M Sell
548
-88
-14% -$403K ﹤0.01% 2314
2014
Q4 		$3.12M Sell
636
-240
-27% -$1.03M ﹤0.01% 2152
2014
Q3 		$3.56M Buy
876
+228
+35% +$855K ﹤0.01% 2022
2014
Q2 		$2.62M Buy
648
+307
+90% +$1.25M ﹤0.01% 2487
2014
Q1 		$1.55M Sell
341
-1,230
-78% -$4.97M ﹤0.01% 2729
2013
Q4 		$5.5M Buy
1,571
+1,123
+251% +$4.38M 0.01% 1761
2013
Q3 		$1.84M Buy
448
+190
+74% +$818K ﹤0.01% 2464
2013
Q2 		$1.02M Buy
+258
New +$1.06M ﹤0.01% 2780

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Credit Suisse's ACOR Position: Q4 2019 in Review

Credit Suisse sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 501 shares — an estimated $172K sold.

Credit Suisse first reported a position in ACOR in Q2 2013 and held it in 26 quarters. The position peaked at $5.5M in Q4 2013. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Credit Suisse reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 501 Acorda Therapeutics shares in Q4 2019, an estimated $172K.
  • Credit Suisse first reported a position in Acorda Therapeutics in Q2 2013 and held it in 26 quarters.
  • Credit Suisse's Acorda Therapeutics position peaked at $5.5M in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.